新型口服抗凝药时代华法林的应用  

Application of warfarin in the era of novel oral anticoagulants

作　　者：卢振华 洪李锋 罗松辉 马业新[2] LU Zhenhua HONG Lifeng LUO Songhui MA Yexin(Department of Cardiology, the Fifth Hospital in Wuhan City, Wuhan, 430050, China Department of Cardiology, Tongji Hospital, HUST)

机构地区：[1]武汉市第五医院心内科,武汉430050 [2]华中科技大学同济医学院附属同济医院心内科

出　　处：《临床心血管病杂志》2016年第11期1083-1086,共4页Journal of Clinical Cardiology

摘　　要：新型口服抗凝药正逐渐作为非瓣膜性心房颤动患者卒中预防的一线抗凝治疗选择。然而新型口服抗凝药价格昂贵,不适用于孕妇、儿童、瓣膜病及严重肾功能不全患者,大多数患者仍需使用华法林抗凝治疗。华法林被推荐用于系统性血栓、卒中、静脉血栓栓塞的防治。新型口服抗凝药时代如何优化华法林抗凝治疗尤为重要。New oral anticoagulants are used increasingly as a first-line treatment for non-valvular atrial fibrillation stroke prevention due to its good efficiency and safety.However,these new oral anticoagulants are expensive and are inappropriate for pregnant women,children,or patients with valvular heart disease or severe renal insufficiency.Therefore,most patients still need to use Warfarin for treatment.Warfarin is recommended for use in the prevention and cure of systemic thrombosis,stroke,and venous thromboembolism.It is of vital importance to optimize the anticoagulant therapy efficacy of Warfarin in the era of novel oral anticoagulants.

关 键 词：新型口服抗凝药 华法林 血栓栓塞 

分 类 号：R542.2[医药卫生—心血管疾病]